$43.74
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Country

US

CEO

Mr. Michael Dale

IPO date

1986

Employees

622

ISIN

US05463X1063

Key stats

Open

$42.77

Volume

1.71M

Market cap

$2.27B

Prev. close

$43.62

Impl / hst vl

-

Open interest

$0.00

$42.77

Day’s Range

$43.89

$27.54

52W Range

$46.95

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
9.95
P/B
9.68
Current ratio
7.10
Debt / Equity
-0.34
ROE
-20.74%
Gross margin
75.16%
Income growth
48.86%
FCF growth
-229.54

Analysts estimates

Consensus rating
Buy

The average rating from top 11 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$51.71
The top 12 analysts forecasts that 12-month price may increase by 18.23%, with a low of $48.48 and a high of $57.75
$48.48
Low
$51.71
Avg
$57.75
High
Current price

Earnings

Q1 ‘26 revenue
$61.46M
Q1 ‘26 net income
-$19.58M
Revenue
Net income
Previous EPS
$0.07
Estimate EPS
$0.13
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply